PET/MRI Delivers Multimodal Brain Signature in Alzheimer’s Disease with De Novo PSEN1 Mutation

Author(s): Gayane Aghakhanyan, Dorothee Saur, Michael Rullmann, Christopher M. Weise, Matthias L. Schroeter, Ken Marek, Rami Abou Jamra, Solveig Tiepolt, Maria Strauss, Cordula Scherlach, Karl-Titus Hoffmann, Osama Sabri, Joseph Classen, Henryk Barthel*

Journal Name: Current Alzheimer Research

Volume 18 , Issue 2 , 2021

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Background: Little is known so far about the brain phenotype and the spatial interplay of different Alzheimer’s disease (AD) biomarkers with structural and functional brain connectivity in the early phase of autosomal-dominant AD (ADAD). Multimodal PET/MRI might be suitable to fill this gap.

Material and Methods: We presented a 31-year-old male patient without a family history of dementia with progressive worsening of memory and motor function. Two separate sessions of 3T PET/MRI acquisitions were arranged with the ß-amyloid tracer [18F]Florbetaben and the secondgeneration tau tracer [18F]PI-2620. Simultaneously acquired MRI consisted of high-resolution 3D T1, diffusion-tensor imaging (DTI), and resting-state fMRI. PET/MRI data were compared with ten age-matched healthy controls.

Results: Widespread β-amyloid depositions were found in cortical regions, and striatum (Thal stage III) along with tau pathology restricted to the mesial-temporal structures (Braak stage III/IV). Volumetric/shape analysis of subcortical structures revealed atrophy of the hippocampal-amygdala complex. In addition, cortical thinning was detected in the right middle temporal pole. Alterations of multiple DTI indices were noted in the major white matter fiber bundles, together with disruption of default mode and sensory-motor network functional connectivity. Molecular genetic analysis by next-generation sequencing revealed a heterozygote missense pathogenic variant of the PSEN1 (Met233Val).

Conclusion : Multimodal PET/MR imaging is able to deliver, in a one-stop-shop approach, an array of molecular, structural and functional brain information in AD due to de novo pathogenic variant, which can be studied for spatial interplay and might provide a rationale for initiating anti- amyloid/tau therapeutic approaches.

Keywords: Amyloid PET, tau PET, autosomal dominant Alzheimer’s disease, hippocampus, PET/MRI, PSEN1, rs-fMRI, DTI

Liu J, Wang Q, Jing D, et al. Diagnostic Approach of early-onset dementia with negative family history: implications from two cases of early-onset Alzheimer’s disease with De Novo PSEN1 mutation. J Alzheimers Dis 2019; 68(2): 551-8.
[] [PMID: 30814350]
Wu L, Rosa-Neto P, Hsiung G-YR, et al. Early-onset familial Alzheimer’s disease (EOFAD). Can J Neurol Sci 2012; 39(4): 436-45.
[] [PMID: 22728850]
De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 2003; 38(1): 9-12.
[] [PMID: 12691659]
Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat 2012; 33(9): 1340-4.
Dumanchin C, Brice A, Campion D, et al. De novo presenilin 1 mutations are rare in clinically sporadic, early onset Alzheimer’s disease cases. J Med Genet 1998; 35(8): 672-3.
[] [PMID: 9719376]
Appel-Cresswell S, Guella I, Lehman A, Foti D, Farrer MJ. PSEN1 p.Met233Val in a complex neurodegenerative movement and neuropsychiatric disorder. J Mov Disord 2018; 11(1): 45-8.
[] [PMID: 29316780]
Houlden H, Crook R, Dolan RJ, McLaughlin J, Revesz T, Hardy J. A novel presenilin mutation (M233V) causing very early onset Alzheimer’s disease with Lewy bodies. Neurosci Lett 2001; 313(1-2): 93-5.
[] [PMID: 11684347]
Barthel H, Gertz H-J, Dresel S, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurol 2011; 10(5): 424-35.
[] [PMID: 21481640]
Tiepolt S, Hesse S, Patt M, Luthardt J, Schroeter ML, Hoffmann K-T, et al. F]florbetaben and [. Eur J Nucl Med Mol Imaging. Eur J Nucl Med Mol Imaging 2016; 1-10.
Kroth H, Oden F, Molette J, et al. Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies. Eur J Nucl Med Mol Imaging 2019; 46(10): 2178-89.
[] [PMID: 31264169]
Gordon BA, Blazey TM, Su Y, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: A longitudinal study. Lancet Neurol 2018; 17(3): 241-50.
[] [PMID: 29397305]
Vöglein J, Paumier K, Jucker M, et al. Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer’s disease. Brain 2019; 142(5): 1429-40.
[] [PMID: 30897203]
Gordon BA, Blazey TM, Christensen J, et al. Tau PET in autosomal dominant Alzheimer’s disease: Relationship with cognition, dementia and other biomarkers. Brain 2019; 142(4): 1063-76.
[] [PMID: 30753379]
Schroeter ML, Stein T, Maslowski N, Neumann J. Neural correlates of Alzheimer’s disease and mild cognitive impairment: A systematic and quantitative meta-analysis involving 1351 patients. Neuroimage 2009; 47(4): 1196-206.
[] [PMID: 19463961]
Douaud G, Behrens TE, Poupon C, et al. In vivo evidence for the selective subcortical degeneration in Huntington's disease. NeuroImage 2009; 46(4): 958-66.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 14 April, 2021
Page: [178 - 184]
Pages: 7
DOI: 10.2174/1567205018666210414111536
Price: $65

Article Metrics

PDF: 33
PRC: 1